TY - JOUR
T1 - Strain-Dependent Inhibition of Erythrocyte Invasion by Monoclonal Antibodies Against Plasmodium falciparum CyRPA
AU - Knudsen, Anne S
AU - Björnsson, Kasper H
AU - Bassi, Maria R
AU - Walker, Melanie R
AU - Kok, Andreas
AU - Cristinoi, Bogdan
AU - Jensen, Anja R
AU - Barfod, Lea
N1 - Copyright © 2021 Knudsen, Björnsson, Bassi, Walker, Kok, Cristinoi, Jensen and Barfod.
PY - 2021
Y1 - 2021
N2 - The highly conserved Plasmodium falciparum cysteine-rich protective antigen (PfCyRPA) is a key target for next-generation vaccines against blood-stage malaria. PfCyRPA constitute the core of a ternary complex, including the reticulocyte binding-like homologous protein 5 (PfRh5) and the Rh5-interacting protein (PfRipr), and is fundamental for merozoite invasion of erythrocytes. In this study, we show that monoclonal antibodies (mAbs) specific to PfCyRPA neutralize the in vitro growth of Ghanaian field isolates as well as numerous laboratory-adapted parasite lines. We identified subsets of mAbs with neutralizing activity that bind to distinct sites on PfCyRPA and that in combination potentiate the neutralizing effect. As antibody responses against multiple merozoite invasion proteins are thought to improve the efficacy of blood-stage vaccines, we also demonstrated that combinations of PfCyRPA- and PfRh5 specific mAbs act synergistically to neutralize parasite growth. Yet, we identified prominent strain-dependent neutralization potencies, which our results suggest is independent of PfCyRPA expression level and polymorphism, demonstrating the importance of addressing functional converseness when evaluating blood-stage vaccine candidates. Finally, our results suggest that blood-stage vaccine efficacy can be improved by directing the antibody response towards defined protective epitopes on multiple parasite antigens.
AB - The highly conserved Plasmodium falciparum cysteine-rich protective antigen (PfCyRPA) is a key target for next-generation vaccines against blood-stage malaria. PfCyRPA constitute the core of a ternary complex, including the reticulocyte binding-like homologous protein 5 (PfRh5) and the Rh5-interacting protein (PfRipr), and is fundamental for merozoite invasion of erythrocytes. In this study, we show that monoclonal antibodies (mAbs) specific to PfCyRPA neutralize the in vitro growth of Ghanaian field isolates as well as numerous laboratory-adapted parasite lines. We identified subsets of mAbs with neutralizing activity that bind to distinct sites on PfCyRPA and that in combination potentiate the neutralizing effect. As antibody responses against multiple merozoite invasion proteins are thought to improve the efficacy of blood-stage vaccines, we also demonstrated that combinations of PfCyRPA- and PfRh5 specific mAbs act synergistically to neutralize parasite growth. Yet, we identified prominent strain-dependent neutralization potencies, which our results suggest is independent of PfCyRPA expression level and polymorphism, demonstrating the importance of addressing functional converseness when evaluating blood-stage vaccine candidates. Finally, our results suggest that blood-stage vaccine efficacy can be improved by directing the antibody response towards defined protective epitopes on multiple parasite antigens.
KW - Animals
KW - Antibodies, Monoclonal/immunology
KW - Antibodies, Neutralizing/immunology
KW - Antigenic Variation/genetics
KW - Antigens, Protozoan/immunology
KW - Dose-Response Relationship, Immunologic
KW - Epitopes/immunology
KW - Erythrocytes/parasitology
KW - Host-Parasite Interactions/immunology
KW - Humans
KW - Malaria Vaccines
KW - Malaria, Falciparum/parasitology
KW - Mice
KW - Neutralization Tests
KW - Plasmodium falciparum/growth & development
KW - Protein Binding/immunology
KW - Protozoan Proteins/immunology
KW - Recombinant Proteins/immunology
KW - Vaccine Efficacy
UR - http://www.scopus.com/inward/record.url?scp=85113415890&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2021.716305
DO - 10.3389/fimmu.2021.716305
M3 - Journal article
C2 - 34447381
VL - 12
SP - 716305
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
M1 - 716305
ER -